Literature DB >> 25179425

Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.

Birgit Hotz1, Ulrike Erben, Marco Arndt, Heinz J Buhr, Hubert G Hotz.   

Abstract

PURPOSE: The taurine derivative taurolidine (TRD) exerts anti-neoplastic effects in a variety of tumor models. On the other hand, TRD at low doses was shown to reduce cell-cell adhesion, a prerequisite for metastasis. The aim of this study was to elucidate the effects of low-dose TRD on pancreatic cancer.
METHODS: Human pancreatic cancer cell lines representing diverse states of differentiation were exposed to TRD for 24 h. Cell viability was assessed by MTT assay and trypan blue staining, apoptosis by caspase-3/7 activity, and flow-cytometric cell cycle analysis. Expression of Snail and E-cadherin was analyzed by polymerase chain reaction and Western blotting.
RESULTS: MTT-tested viability of all pancreatic cancer cell lines decreased dose-dependently up to 50 % of the untreated control. In contrast to staurosporine TRD (100 and 250 μM) did not induce apoptosis but increased the percentage of cells in G1/G0 arrest. Correlation of MTT test and trypan blue staining revealed a decreased adherence of vital tumor cells at 250 μM TRD. This was associated with reduced expression of the adhesion molecule E-cadherin and an increased expression of the transcription factor Snail, a regulator of epithelial-mesenchymal transition (EMT).
CONCLUSION: Low-dose TRD reduces not only viability but also cell-cell adherence and E-cadherin expression of pancreatic cancer cells, whereas the expression of the EMT inducer Snail was increased. By induction of these EMT hallmarks, low-dose TRD may promote metastasis in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25179425     DOI: 10.1007/s00384-014-1998-4

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  41 in total

1.  Snail silencing effectively suppresses tumour growth and invasiveness.

Authors:  D Olmeda; M Jordá; H Peinado; A Fabra; A Cano
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

2.  Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer.

Authors:  H-F Yuen; C-W Chua; Y-P Chan; Y-C Wong; X Wang; K-W Chan
Journal:  Histopathology       Date:  2007-04       Impact factor: 5.087

Review 3.  Current standards of surgery for pancreatic cancer.

Authors:  N Alexakis; C Halloran; M Raraty; P Ghaneh; R Sutton; J P Neoptolemos
Journal:  Br J Surg       Date:  2004-11       Impact factor: 6.939

4.  Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats.

Authors:  G Nestler; H U Schulz; D Schubert; S Krüger; H Lippert; M Pross
Journal:  Surg Endosc       Date:  2004-12-09       Impact factor: 4.584

5.  Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo.

Authors:  Claudia Abramjuk; Michael Bueschges; Jörg Schnorr; Klaus Jung; Andrea Staack; Michael Lein
Journal:  Oncol Rep       Date:  2009-08       Impact factor: 3.906

Review 6.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

Review 7.  The role of epithelial-mesenchymal transition in cancer pathology.

Authors:  Marcello Guarino; Barbara Rubino; Gianmario Ballabio
Journal:  Pathology       Date:  2007-06       Impact factor: 5.306

8.  Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients.

Authors:  Ruediger Stendel; Louis Scheurer; Kathrin Schlatterer; Urs Stalder; Rolf W Pfirrmann; Ingo Fiss; Hanns Möhler; Laurent Bigler
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Gene expression analysis of cell death induction by taurolidine in different malignant cell lines.

Authors:  Ansgar M Chromik; Stephan A Hahn; Adrien Daigeler; Annegret Flier; Daniel Bulut; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Dirk Weyhe; Ulrich Mittelkötter; Waldemar Uhl
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

Review 10.  Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma.

Authors:  Carla E Cano; Yoshiharu Motoo; Juan L Iovanna
Journal:  ScientificWorldJournal       Date:  2010-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.